Navigation Links
Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease
Date:11/10/2008

understanding of cysteamine's effects in Huntington's patients and we hope it may lead to a new treatment for this serious, debilitating disease."

The primary endpoint of the Phase II trial will be evaluated using the Unified Hungtington's Disease Rating Scale ("UHDRS"). The secondary endpoint will measure brain-derived neurotrophic factor ("BDNF") levels, known to be deficient in Huntington's patients. A preclinical study published by Drs. Sandrine Humbert and Frederic Saudou from the Curie Institute demonstrated a potential mechanism for cysteamine in an in vivo preclinical Huntington's model that showed increased brain and blood levels of BDNF. The Curie Institute will participate in the clinical trial by determining the BDNF levels in the patients.

About Huntington's Disease

Huntington's is a rare, progressive, and hereditary neurological disease that often leads to death within 15 to 20 years after diagnosis. The disease is thought to affect as many as 20,000 patients in the U.S. There is no currently available drug that targets the defective gene believed to cause Huntington's, which results in the degeneration of certain nerve cells in the brain. The disease is characterized by uncontrollable movements and mood swings or depression, followed by dementia.

About Cysteamine and DR Cysteamine

Cysteamine is approved for sale by the FDA and European Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), a rare, genetic lysosomal storage disease. DR Cysteamine is designed as an enterically coated, proprietary oral formulation of cysteamine to potentially reduce dosing frequency and gastrointestinal side effects.

Raptor obtained an exclusive, worldwide license from the University of California, San Diego ("UCSD") for the development of cysteamine and DR Cysteamine for a number of potential indications including Huntington's, cystinosis, non-alcoholic steatohepatitis ("NASH") and Batten Disease. Raptor is
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update on Targeting Platforms
2. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
5. Raptor Pharmaceuticals Provides Update of Product Programs
6. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
7. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
8. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
11. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  The need to add tissue preserving therapies ... prominently at the 108 th Annual Meeting ... Diego.  According to SonaCare Medical, a leader in ... the need for image-guided technologies to better identify ... minimally invasive ablative treatments, was addressed in the ...
(Date:5/23/2013)... , May 23, 2013  Hologic, Inc. ... ), a leading developer, manufacturer and supplier of ... with an emphasis on serving the healthcare needs ... observational study in a U.S. clinical practice comparing ... (breast tomosynthesis) with conventional 2D mammography alone showed ...
(Date:5/23/2013)... N.M. , May 23, 2013  Net Medical ... the telemedicine market, announced today the company has signed ... telemedicine staffing company based in Huntsville, AL ... that specializes in the staffing and recruitment of telemedicine ... completion of the final agreement, which is expected by ...
Breaking Medicine Technology:Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3
... HAIFA, Israel, October 26 Cardio Vascular,Medical Device Corp. ... today released a brief shareholders update. , ... patent for an innovative,next-generation "steerable guidewire" applicable for all ... become the guidewire of,choice for surgeons throughout the world. ...
... Oct. 26 Symmetry Medical Inc. (NYSE: SMA ... global orthopaedic device industry and other medical markets, announced ... Based on recent diminished order flow resulting from lower ... in both orthopaedic and non-orthopaedic markets, Symmetry is adjusting ...
Cached Medicine Technology:Cardio Vascular Medical Device Sends Update to Shareholders 2Symmetry Medical Updates Full Year 2009 Financial Guidance 2Symmetry Medical Updates Full Year 2009 Financial Guidance 3
(Date:5/25/2013)... Life science and analytical reagents are ... and create a new substance with the purpose of ... known as biotechnology reagents. Such reagents are significant in ... This market is driven by factors such as expansion ... therapeutics, growth in research and rapid commercialization of such ...
(Date:5/25/2013)... News) -- Many viruses and parasites that affect both ... a bacteria-borne illness than can result in liver or ... according to a veterinarian. These germs could ... air, said Dr. Susan Nelson, a clinical associate professor ... these serious diseases can be fatal, even with treatment," ...
(Date:5/25/2013)... 25, 2013 Studies from Johns Hopkins ... carrying excessive weight and their inability to get adequate ... losing weight can naturally relieve many symptoms. , ... in sleep quality was significantly associated with overall weight ... study dated November 6th, 2012, researchers monitored 77 ...
(Date:5/25/2013)... 25, 2013 Pradaxa lawsuits ... episodes of internal bleeding while using the blood thinner continue ... Court, Southern District of Illinois, Bernstein Liebhard LLP reports. ... side effect claims had been filed in the ... 705 claims reported by the Court on May 15th. ( ...
(Date:5/25/2013)... 25, 2013 According to a ... Market, 2013–2018", published by MarketsandMarkets is expected to ... of 5.54% which analyzes and studies the major ... Europe, Asia, and Rest of the World. , ... Tables , 87 Figures , ...
Breaking Medicine News(10 mins):Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 2Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 3Health News:Hidden Dangers Dog Dog Parks 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4
... PITTSBURGH, April 29 Mylan Inc. (NYSE: ... Michael J. Monroe as senior vice,president - ... of the company,s senior,leadership team. In this ... and employee communications; corporate,branding/marketing; corporate media relations; ...
... also contributed to early dropout rate, study says , , ... problem drug users, and those not currently injecting drugs, ... a British study finds. , University of Kent and ... drug users in treatment programs and found that 25 ...
... Society finds cancer survivors who follow health behavior recommendations ... getting adequate exercisehave higher health-related quality of life (HRQoL) ... The study, which appears in the May issue of ... have low rates of smoking, but few are meeting ...
... factor most commonly used to predict whether an extremely ... that can help predict a preemies outcome have been ... Network, of which Yale is a member. , ... and whether the mother was given antenatal steroid mediation ...
... New York, NY -- A JDRF collaboration between Johns ... for the treatment of diabetic eye disease has performed ... using laser surgery. , These findings, representing the ... by The Johns Hopkins University, were presented Monday at ...
... Layoffs and Loss of Healthcare Services, PRINCETON, N.J., ... drives and longer waits for care.,Those are among the ... state,s $300 million in proposed healthcare cuts are approved., ... healthcare leaders from across,the state met with Gov. Jon ...
Cached Medicine News:Health News:Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs 2Health News:Youngest Drug Users Most Likely to Leave Treatment Programs 2Health News:Cancer survivors who practice healthy habits have higher quality of life 2Health News:Factors affecting survival, disability of extremely premature infants identified 2Health News:Promising early evidence of the superior benefits of drug therapy for diabetic eye disease 2Health News:Hospital CEOs Meet with Governor on Budget Cuts 2
... Kendall provides hospitals and alternate care ... tracheostomy care trays which offer the ... control. Designed with the guidance of ... trays provide exactly what is required ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
... KIMBERLY-CLARK BALLARD Component Kit ... Elbows and Double Swivel ... Customer-oriented presentation to meet ... Also available in neonatal ...
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions....
Medicine Products: